---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-052419"
form_type: "8-K"
ticker: null
cik: "0001260990"
company_name: "Oncternal Therapeutics, Inc."
filed_at: "2023-10-06T23:59:59+00:00"
generated_at: "2026-06-10T03:15:20.332751+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oncternal gets 180-day Nasdaq extension to April 1, 2024 to regain bid price compliance

## Summary
- Nasdaq granted an additional 180 days, to April 1, 2024, to meet the $1.00 minimum bid price rule.
- Original non-compliance notice issued April 4, 2023 after bid closed below $1.00 for 30 consecutive days.
- Stockholders approved a reverse stock split (1:5 to 1:30) at June 28, 2023 annual meeting to cure deficiency.
- If not compliant by April 1, 2024, Nasdaq will issue delisting notice; company may appeal.
- No assurance compliance will be regained or that other listing requirements will be maintained.

## SEC filing metadata
- accession: 0000950170-23-052419
- form_type: 8-K
- cik: 0001260990
- company_name: Oncternal Therapeutics, Inc.
- filed_at: 2023-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1260990/000095017023052419/0000950170-23-052419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1260990/000095017023052419/onct-20231003.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-052419
- JSON: https://secwatch.observer/filing/0000950170-23-052419.json
- Plain text: https://secwatch.observer/filing/0000950170-23-052419.txt

## Key facts
- Listing & Compliance Notices
  Oncternal Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: October 3, 2023, Nasdaq notified Oncternal that it has granted Oncternal an additional 180 calendar days, or to April 1, 2024, to regain compliance with the Minimum Bid Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). Oncternal intends to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. Specifically, Oncternal has confirmed to Nasdaq that, if necessary, it will implement a reverse stock split of its outstanding common stock, to attempt to regain compliance. At Onct
  evidence_url: https://www.sec.gov/Archives/edgar/data/1260990/000095017023052419/0000950170-23-052419-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.